Shots:

• The 1st patient has been dosed in the P-II MARCH trial evaluating safety- tolerability & efficacy of VIR-2218 + VIR-3434 (SC) in ~90 patients aged 18-65yrs. with chronic HBV infection for 4-20wks. & follow-up period of ~116 wks.- depend on dosing cohort
• The 1EPs of a trial is the proportion of patients with AEs & SAEs- grading of post-treatment clinical laboratory parameters & proportion of patients achieving a functional cure
• VIR-2218 is an investigational HBV-targeting siRNA & VIR-3434 is an HBV-neutralizing mAb designed to block entry of all 10 genotypes of HBV into hepatocytes- as well as reduce the level of virions and subviral particles in the blood

 Ref: Vir | Image: Fierce Biotech